Henan Newland Pharmaceutical Co. Ltd. A (301277.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000065K2

Price
8.75 CNY
Market cap
3.43 bn CNY
P/E (2025)
28.29
P/S (2025)
5.10
Dividend yield
2.29 %
Net margin
18.03 %
Return on equity (ROE)
7.82 %
Return on assets (ROA)
6.81 %

Henan Newland Pharmaceutical Co. Ltd. A financials

Fiscal year20242025
Revenue726.44 m CNY672.38 m CNY
Gross profit294.58 m CNY234.74 m CNY
Operating income191.36 m CNY133.36 m CNY
EBIT197.44 m CNY134.34 m CNY
Net income173.63 m CNY121.25 m CNY
Diluted EPS – continuing operations0.44 CNY0.31 CNY

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Henan Newland Pharmaceutical Co. Ltd. A

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.